AVROBIO Email Format
Biotechnology ResearchMassachusetts, United States11-50 Employees
AVROBIO is a biotechnology company pursuing personalized gene therapies that aim to address genetic disease at its source. It introduces a functional copy of the defective gene into patients' own hematopoietic stem cells, with the goal of producing the therapeutic protein throughout the body, including the central nervous system. The company relies on its plato gene therapy platform to support development and potential global use. Its clinical pipeline includes Gaucher disease and Hunter syndrome, with a preclinical program for Pompe disease. Headquartered in Cambridge, Massachusetts, the company is a smaller biotechnology firm focused on therapies delivered via patients' own hematopoietic stem cells. In 2024, AVROBIO announced a merger with Tectonic Therapeutic, a development noted in public disclosures.